Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies for neurodegenerative, metabolic, and alcohol misuse disorders. The company's diversified platform spans clinical-stage therapeutics, consumer-focused wellness products, and strategic investments, aiming to generate multiple revenue streams and support long-term growth.
According to a recent article highlighting the company, Quantum BioPharma's strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures. The article notes that the company is advancing programs across multiple stages of development while leveraging scientific research, intellectual property, and commercial relationships as part of its broader business strategy. The full article is available at https://ibn.fm/JtLc5.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., a company led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd, as noted at www.unbuzzd.com. The agreement includes royalty payments of 7% of sales from UNBUZZD until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
Quantum BioPharma's approach positions it to address areas of significant unmet need, with a pipeline that includes drug candidates in different stages of development. The company's focus on neurodegenerative and metabolic disorders, along with alcohol misuse, reflects a commitment to tackling challenging health conditions through innovative science and strategic partnerships.
For the latest news and updates relating to QNTM, visit the company's newsroom at https://ibn.fm/QNTM.
